Cancer and Gene Regulation
Cancer is fundamentally a disease of gene regulation. When the genes controlling cell growth and division accumulate mutations or undergo abnormal epigenetic changes, cells can escape normal controls and divide without limit. This topic ties together everything you've learned about gene expression, the cell cycle, and mutation.
Gene Expression in Cancer Development
Cancer doesn't usually result from a single mutation. It arises from the accumulation of multiple mutations in genes that regulate cell growth and division. Two major categories of genes are involved:
- Proto-oncogenes normally promote cell growth and division (examples: RAS, MYC). When a proto-oncogene is mutated, it can become an oncogene, a permanently "on" version that drives uncontrolled cell growth. Think of it like a gas pedal stuck to the floor.
- Tumor suppressor genes normally inhibit cell growth and division (examples: p53, RB). When these genes are inactivated by mutation, the cell loses its brakes. Both copies of a tumor suppressor gene typically need to be knocked out before the effect is seen (this is called the two-hit hypothesis).
Epigenetic changes also contribute to cancer, even without altering the DNA sequence itself:
- DNA methylation: Adding methyl groups to promoter regions can silence tumor suppressor genes, effectively shutting them off.
- Histone modifications: Changes like acetylation or methylation of histone proteins can loosen or tighten chromatin, promoting or suppressing the expression of genes involved in cancer development.
Environmental factors matter too. Exposure to carcinogens (UV radiation, tobacco smoke, certain chemicals) can directly damage DNA and cause the mutations that initiate cancer.
Gene Regulation and the Cell Cycle
The cell cycle is controlled by a system of proteins that act as internal checkpoints. The two key players are cyclins and cyclin-dependent kinases (CDKs):
- Cyclins (such as cyclin D and cyclin E) rise and fall in concentration at specific phases of the cell cycle, acting as timing signals.
- CDKs (such as and ) are enzymes that, when bound to their cyclin partner, phosphorylate target proteins to push the cell into the next phase of the cycle.
When this system breaks down, cancer can result:
- Overexpression of cyclins or CDKs causes cells to divide too frequently.
- Inactivation of CDK inhibitors (such as p21 and p27) removes another layer of growth control, also leading to excessive division.
The p53 protein deserves special attention. It's often called the "guardian of the genome" because it responds to DNA damage or cellular stress by either halting the cell cycle (giving the cell time to repair) or triggering apoptosis (programmed cell death) if the damage is too severe. Mutations in p53 are found in over 50% of human cancers. A germline mutation in p53 causes Li-Fraumeni syndrome, a hereditary condition with dramatically increased cancer risk.
Checkpoint proteins throughout the cell cycle monitor for abnormalities like unreplicated DNA or chromosome misalignment. If something is wrong, they halt progression until the problem is fixed. Loss of checkpoint function is another common feature of cancer cells.
Cancer Progression and Metastasis
A tumor doesn't just grow in isolation. Several processes allow it to become more dangerous over time:
- Angiogenesis: Tumors stimulate the formation of new blood vessels to supply themselves with nutrients and oxygen. Without angiogenesis, a tumor can't grow beyond a few millimeters.
- Metastasis: Cancer cells break away from the primary tumor, enter the bloodstream or lymphatic system, and establish new tumors in distant organs. This is what makes cancer so difficult to treat and is responsible for most cancer deaths.
- Tumor microenvironment: The surrounding non-cancerous cells, immune cells, and extracellular matrix all influence whether a tumor grows, stays dormant, or spreads.
- Telomerase activation: Normal cells can only divide a limited number of times because their telomeres shorten with each division. Most cancer cells reactivate telomerase, an enzyme that maintains telomere length, giving them essentially unlimited replicative potential.
Molecular Insights for Cancer Therapies
Understanding the specific molecular pathways driving a cancer has opened the door to targeted therapies that are far more precise than traditional chemotherapy.
- Kinase inhibitors block overactive signaling enzymes. For example, imatinib targets the BCR-ABL fusion protein in chronic myeloid leukemia, a kinase that is always active due to a chromosomal translocation.
- Monoclonal antibodies bind to specific proteins on cancer cell surfaces. Trastuzumab targets the HER2 receptor, which is overexpressed in some breast cancers.
Epigenetic therapies aim to reverse abnormal gene silencing in cancer cells:
- DNA methyltransferase inhibitors (such as azacitidine) block the enzymes that add methyl groups, helping to reactivate silenced tumor suppressor genes.
- Histone deacetylase (HDAC) inhibitors (such as vorinostat) increase histone acetylation, loosening chromatin and promoting expression of tumor suppressor genes.
Personalized medicine uses genetic and molecular profiling of a patient's tumor to guide treatment decisions:
- Identifying specific mutations (such as EGFR mutations in lung cancer) helps doctors select the targeted therapy most likely to work.
- Monitoring cancer biomarkers (such as PSA levels in prostate cancer) helps track treatment response and detect relapse early.